Current Surgical Inc., a medical technology company, has been awarded a $400,000 grant by the National Institutes of Health's National Cancer Institute (NCI) to support the advancement of their surgical platform for early-stage cancer. The grant will be utilized to further develop and validate the company's innovative technology in a preclinical setting.
With over 18 million new cases detected annually, cancer remains one of the leading causes of death worldwide. Despite advancements in early detection rates, treatment options have not kept pace with the increasing demand. Current Surgical is determined to change this by creating an intelligent surgical needle technology that integrates high-resolution sensors and real-time image analysis into a single tool. This groundbreaking technology will provide surgeons with precise control and immediate feedback during tumor destruction, enabling them to effectively treat any solid tumor regardless of its location.
The funding from the NCI will expedite the development process of Current Surgical's platform and hasten its availability to patients. The company firmly believes that their technology has the potential to revolutionize cancer surgery by enhancing accuracy and precision while reducing complications.
In addition